Drug profile · INN
glycerol phenylbutyrate
RAVICTI
glycerol phenylbutyrate (RAVICTI) is a glutamine sequestering agent. Associated with Teva Pharma GmbH. Route of administration: oral. Current US regulatory status: approved.
Drug details — glycerol phenylbutyrate
- US status
- approved
- Class
- Alimentary tract and metabolism (A16)
- Route
- ORAL
- Patents
- 20
- Programs
- 2
- Data quality
- 0.89
Quick answer
glycerol phenylbutyrate (RAVICTI) is a glutamine sequestering agent. Associated with Teva Pharma GmbH. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Glutamine sequestering agent
Primary target: Glutamine
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | approved | — |
Pipeline programs
Related & competitor drugs
Related patents
-
US 12202822
Addition salt of S1P1 receptor agonist and crystal form thereof, and pharmaceutical composition
granted -
US 12018255
Compositions and methods for treating disorders of genomic imprinting
granted -
US 11952419
Reagents and methods for treating cancer and autoimmune disease
granted -
US 11833254
Discoidal nano universal platform for efficient delivery of PNAs
granted -
US 11512078
Addition salt of S1P1 receptor agonist and crystal form thereof, and pharmaceutical composition
granted -
US 11497197
Methods for enhancing poultry growth and performance
granted -
US 11479617
Chelator-functionalized glycosaminoglycans
granted -
US 11390613
Azole analogues and methods of use thereof
granted -
US 11364309
Neuronal enhancers
granted -
US 11103523
Self-assembled brush block copolymer-nanoparticles for drug delivery
granted -
US 11008378
Compositions and methods for immunomodulation in an organism
granted -
US 10814006
Fluorescent prodrugs
granted -
US 10464993
Compositions and methods for immunomodulation in an organism
granted -
US 10344040
Pyridone and aza-pyridone compounds and methods of use
granted -
US 10280158
Immune adjustment compound, use thereof and pharmaceutical composition comprising same
granted -
US 10053469
Pyridone and aza-pyridone compounds and methods of use
granted -
US 9969790
Compositions and methods for immunomodulation in an organism
granted -
US 9932387
Compositions and methods for immunomodulation in an organism
granted -
US 9796718
6-(benzo[d]thiazol-5-yl)-n-(3,4-dimethoxyphenyl)imidazo[1,2-a]pyrazin-8-amine
granted -
US 9636424
Composition, method, system and kit for optical electrophysiology
granted
Frequently asked questions
What is glycerol phenylbutyrate?
glycerol phenylbutyrate (RAVICTI) is a glutamine sequestering agent. Associated with Teva Pharma GmbH. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for glycerol phenylbutyrate?
RAVICTI is a marketed brand name for glycerol phenylbutyrate. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of glycerol phenylbutyrate?
glycerol phenylbutyrate has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.